Firms Foresee High Stakes In Emerging Biopesticide Market

Genetic engineers at Crop Genetics and Mycogen place hopes on two different strategies for pest control Like Babe Ruth, John Henry sees himself as a slugger. The president and CEO of Crop Genetics International of Hanover, Md., Henry is going for a grand slam in his field of pest control: a genetically designed biopesticide against the European corn borer, a pest that munches $500 million worth of corn annually in the United States. In contrast to his heavy-hitting strategy are the efforts of

Written byRenee Twombly
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share


Genetic engineers at Crop Genetics and Mycogen place hopes on two different strategies for pest control
Like Babe Ruth, John Henry sees himself as a slugger. The president and CEO of Crop Genetics International of Hanover, Md., Henry is going for a grand slam in his field of pest control: a genetically designed biopesticide against the European corn borer, a pest that munches $500 million worth of corn annually in the United States. In contrast to his heavy-hitting strategy are the efforts of competing firms, which, according to Henry, are only "trying to hit singles."

John Henry may owe his interest in modernizing agriculture to, well, his genes. A distant ancestor, Cyrus McCormick, invented the reaping machine in 1831, and parlayed that into what is now International Harvester Corp. Henry wants to help usher in the next revolution in agriculture - designing a plant vaccine for the world's grain crops ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies